Harnessing Open‐Source Solutions: Insights From the First Open Systems Pharmacology ( OSP ) Community Conference

CPT Pharmacometrics & Systems Pharmacology, vol. 14, pp. 822–827

Abstract

In 2017, the free and open-source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open-source solutions for model-informed drug development (MIDD). In this context, the first OSP Community Conference was hosted by Novartis in Basel, Switzerland, on October 7-8, 2024, which gathered over 100 attendees from more than 40 institutions. This perspective synthesizes key insights from the conference.

Authors 32

1. André Dallmann corresponding
   Affiliation as printed

   Bayer HealthCare SAS Lille France

2. Denise Feick

   Sanofi (Germany)

   Affiliation as printed

   DMPK Modeling & Simulation Sanofi R&D Frankfurt am Main Germany

3. Pavel Balazki
   Affiliation as printed

   ESQlabs GmbH Saterland Germany

4. Salih Benamara

   Centre National de la Recherche Scientifique · Inserm · Aix-Marseille Université · Sanofi (France)

   Affiliation as printed

   Computational Pharmacology and Clinical Oncology, Inserm UMR1068, CNRS Aix Marseille University Marseille France

   Translational Medicine & Early Development Sanofi R&D Vitry‐sur‐Seine France

5. Rolf Burghaus

   Bayer (Germany)

   Affiliation as printed

   Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany

6. Marylore Chenel
   Affiliation as printed

   Pharmetheus AB Uppsala Sweden

7. Siak‐Leng Choi

   Sanofi (France)

   Affiliation as printed

   DMPK Modeling & Simulation Sanofi‐Aventis R&D Vitry‐sur‐Seine France

8. Henrik Cordes

   Sanofi (Germany)

   Affiliation as printed

   DMPK Modeling & Simulation Sanofi R&D Frankfurt am Main Germany

9. Mariana Guimarães
   Affiliation as printed

   ESQlabs GmbH Saterland Germany

10. Abdullah Hamadeh

    University of Waterloo

    Affiliation as printed

    School of Pharmacy University of Waterloo Kitchener Ontario Canada

11. Ibrahim Ince

    Boehringer Ingelheim (Germany)

    Affiliation as printed

    Clinical Pharmacology Boehringer Ingelheim Pharma GmbH & co. KG Ingelheim am Rhein Germany

12. Kathleen M. Job

    University of Utah

    Affiliation as printed

    Division of Clinical Pharmacology, Department of Pediatrics, School of Medicine The University of Utah Salt Lake City Utah USA

13. Tobias Kanacher
    Affiliation as printed

    Pharmetheus AB Uppsala Sweden

14. Andreas Kovar

    Sanofi (Germany)

    Affiliation as printed

    DMPK Modeling & Simulation Sanofi R&D Frankfurt am Main Germany

15. Lars Kuepfer Aachen Institute for Systems Medicine with Focus on Organ Interaction

    Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Institute for Systems Medicine With Focus on Organ Interaction University Hospital RWTH Aachen Aachen Germany

16. Jörg Lippert

    Bayer (Germany)

    Affiliation as printed

    Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany

17. Julia Macente

    KU Leuven

    Affiliation as printed

    Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium

18. Nina Nauwelaerts

    KU Leuven

    Affiliation as printed

    Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium

    ESQlabs GmbH Saterland Germany

19. Christoph Niederalt

    Bayer (Germany)

    Affiliation as printed

    Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany

20. Sheila Annie Peters

    Boehringer Ingelheim (Germany)

    Affiliation as printed

    Clinical Pharmacology Boehringer Ingelheim Pharma GmbH & co. KG Ingelheim am Rhein Germany

21. Susana Proença
    Affiliation as printed

    ESQlabs GmbH Saterland Germany

22. Masanobu Sato

    Boehringer Ingelheim (Germany)

    Affiliation as printed

    Clinical Pharmacology Boehringer Ingelheim Pharma GmbH & co. KG Ingelheim am Rhein Germany

23. Stephan Schaller
    Affiliation as printed

    ESQlabs GmbH Saterland Germany

24. Jan‐Frederik Schlender

    Novartis (Switzerland) · Novartis Institutes for BioMedical Research

    Affiliation as printed

    Biomedical Research Novartis Basel Switzerland

25. Annika R. P. Schneider

    Bayer (Germany)

    Affiliation as printed

    Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany

26. Erik Sjögren

    Uppsala University

    Affiliation as printed

    Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden

    Pharmetheus AB Uppsala Sweden

27. Juri Solodenko

    Bayer (Germany)

    Affiliation as printed

    Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany

28. Alexander Staab

    Boehringer Ingelheim (Germany)

    Affiliation as printed

    Clinical Pharmacology Boehringer Ingelheim Pharma GmbH & co. KG Ingelheim am Rhein Germany

29. Paul Vrenken

    National and Kapodistrian University of Athens

    Affiliation as printed

    National and Kapodistrian University of Athens Department of Pharmacy Zografou Greece

30. Thomas Wendl

    Bayer (Germany)

    Affiliation as printed

    Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany

31. Wilhelmus E. A. de Witte
    Affiliation as printed

    ESQlabs GmbH Saterland Germany

32. Donato Teutonico

    Sanofi (France)

    Affiliation as printed

    Translational Medicine & Early Development Sanofi R&D Vitry‐sur‐Seine France